大家好！
这里是集才华与美貌与性感与骚气的大胸xie
今天是周一！
优秀的青年们，别忘了读文献哦~
1
（向上滑动起阅）
Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation
面朝大海
春暖花开
BACKGROUND: The role of epidermal growth factor receptor (EGFR) pathways in regulating telomerase is increasingly being recognised. We analysed the impact of rs2853669 single nucleotide polymorphism (SNP) on telomere parameters and its prognostic value for non-small cell lung cancer (NSCLC) with or without EGFR mutation.
METHODS: The association of rs2853669 with telomerase reverse transcriptase (TERT) mRNA level and relative telomere length (RTL) was analysed using resected tumour samples from 250 NSCLC patients. We also investigated the patients" clinical outcomes with a median follow-up of 57 months (2-99 months).
RESULTS: The rs2853669 T/C allele was significantly associated with lower TERT mRNA expression (versus C/C and versus T/T; p < 0.001 for both) and shorter RTL (versus C/C and versus T/T; p = 0.039 and 0.023) in patients without EGFR mutation. Such difference was not observed in their counterparts harbouring EGFR mutation. When considering the cohort as a whole, T/C allele was significantly associated with shortest overall survival compared with T/T or C/C allele (mean: 61.8, 80.9 and 88.7 months, plog-rank < 0.001) and disease-free survival (mean: 78.3, 87.9 and 91.5 months, plog-rank = 0.019). Stratification analyses showed that the negative prognostic effect of T/C on OS was constrained in patients without EGFR mutation.
CONCLUSION: Our study revealed significant associations of a common SNP within TERT promoter region on telomere parameters and survival in NSCLC patients without EGFR mutation. The result may help providing instruction for therapeutic interventions targeting telomerase and evidence for investigation of TERT-EGFR interacting mechanism in telomere biology.
【Journal】Eur J Cancer
【IF】6.680
【标题】鉴别有无表皮生长因子受体突变的非小细胞肺癌中常见端粒酶逆转录酶启动子多态性与端粒参数的关联
【摘要】表皮生长因子受体(EGFR)通路在调节端粒酶中的作用越来越受到重视。在这项研究中，作者分析了rs2853669单核苷酸多态性对有无EGFR突变的非小细胞肺癌端粒参数的影响及其预后价值。作者选取了250例非小细胞肺癌切除肿瘤标本，分析端粒酶逆转录酶mRNA水平及相对端粒长度的关系。同时作者还调查了患者的临床结果，平均随访57个月(2-99个月)。作者发现，rs2853669 T/C等位基因与较低的TERT mRNA表达显着相关(与C/C和T/T相比;和较短的RTL(与C/C和T/T相比;无EGFR突变的患者p = 0.039和0.023)。在携带EGFR突变的对照中没有观察到这种差异，总体生存期和无病生存期显着相关。分层分析显示，在没有EGFR突变的患者中，T/C对OS的负预后影响受到限制。作者认为TERT启动子区域内一个共同的SNP对无EGFR突变的非小细胞肺癌患者端粒参数和生存率的显着相关性。此项研究结果可为端粒酶靶向治疗提供指导，为研究端粒生物学中TERT-EGFR相互作用机制提供依据。
【DOI】10.1016/j.ejca..06.024
2
（向上滑动起阅）
Clinical Factors Predictive of a Better Prognosis of Pulmonary Metastasectomy for Hepatocellular Carcinoma
面朝大海
春暖花开
BACKGROUND: Lung is the most common site of extrahepatic metastasis of hepatocellular carcinoma (HCC). The aim of this study was to identify prognostic factors for pulmonary metastasectomy of HCC.
METHODS: 103 patients who underwent pulmonary metastasectomy for HCC between January and December were retrospectively evaluated. Patient demographic >
RESULTS: Of 103 patients, 75 (72.8%) had one site pulmonary metastasis, 22 (21.4%) had two, and six (5.8%) had three or more. Liver recurrence at the time of pulmonary metastasectomy was noted in 34 patients. The estimated 5-year overall survival (OS) rate was 38.5% after pulmonary metastasectomy. Univariate prognostic analysis showed that liver recurrence at the time of pulmonary metastasectomy, extent of resection, laterality of pulmonary metastasis, tumor location, number of metastatic sites, and metastatic tumor size were significantly associated with favorable OS after pulmonary metastasectomy. Multivariate analysis revealed that liver recurrence at the time of pulmonary metastasectomy and the number of metastatic sites were independent prognostic factors. Subgroup analysis with a combination of these two independent prognostic factors revealed 5-year OS rates for patients with zero, one, and two risk factors of 58.5%, 23.8%, and 0.0%, respectively.
CONCLUSIONS: Pulmonary metastasectomy is safe and effective treatment for well-selected patients with pulmonary metastasis of HCC. Liver recurrence at the time of pulmonary metastasectomy and the number of metastatic sites were identified as independent prognostic factors. The number of risk factors significantly influenced patient survival.
【Journal】Ann Thorac Surg
【IF】3.919
【标题】肝细胞癌肺转移瘤预后的临床因素预测
【摘要】肺是肝细胞癌最常见的肝外转移部位。该研究的目的是确定肝癌肺转移瘤切除术的预后因素。作者回顾性分析了1月至12月间103例肝癌肺转移瘤切除术患者的临床资料并研究患者人口学资料及原发性肿瘤和肺转移的特点，以确定与预后显着相关的因素。结果在103例患者中，75例有1处肺转移，22例有2处，6例有3处及以上转移。34例肺转移瘤切除术后肝复发。肺转移瘤切除术后5年总体生存率为38.5%。多因素分析显示，肺转移瘤切除时的肝复发和转移部位的数量是独立的预后因素。由此，作者得出结论，肝细胞癌肺转移瘤切除是一种安全有效的治疗方法。肺转移瘤切除时的肝复发和转移部位的数量被确定为独立的预后因素。危险因素的数量显着影响患者的生存
【DOI】10.1016/j.athoracsur..06.086
3
（向上滑动起阅）
Salvage surgery after chemo- or chemoradiotherapy for initially unresectable lung carcinoma
面朝大海
春暖花开
BACKGROUND: Salvage surgery is used for resection of loco-regionally recurrent or re-growing lesions after treatment for unresectable non-small cell lung cancer. It is also used to resect lesions that have regressed following treatment and that had not initially been indicated for resection. Relationships between salvage surgery, safety and prognosis, however, have remained unclear.
METHODS: Between and , 29 patients received salvage resection (median age: 60 years, 25 men and 4 women). Safety and prognosis were analyzed.
RESULTS: Tumor grade at the time of initial treatment was Stage III or IV in 23 and 6 patients, respectively. Twenty-two patients received chemoradiotherapy (radiation: 40-66 Gy) and seven received chemotherapy. Time from initial treatment to surgery ranged from 2-60 months. Segmentectomy, lobectomy, bi-lobectomy and pneumonectomy were performed in 1, 25, 2, and 1 patient, respectively. Combined resections were needed in 17 patients; this included 10 bronchoplasties, 9 pulmonary arterioplasties, 4 chest wall resections, and 1 great vessel resection. There was no 30-day postoperative mortality. Grade 3 or higher-grade postoperative complications (mostly cardiopulmonary) were observed in 11 patients. Five-year overall survival after initial treatment was 61%; after surgery it was 51%. Five-year relapse-free survival after surgery was 49%. On recurrent-free survival, patients with clinical stage III at the initial treatment, pathological stage 0-II, or a good response to initial treatment showed a favorable prognosis.
CONCLUSIONS: Although cardiopulmonary complications can accompany salvage surgery, the procedure is generally safe. Survival outcome is encouraging, especially in cases with good response to initial treatment.
【Journal】Ann Thorac Surg
【IF】3.919
【标题】早期不可切除肺癌放化疗后的抢救手术
【摘要】对于不可切除的非小细胞肺癌，抢救手术用于切除局部复发或再生长的病灶，它也用于切除治疗后复发的病变。然而，抢救手术、安全性和预后之间的关系仍不清楚。作者研究了至，29例患者接受了挽救性切除(中位年龄:60岁，男性25例，女性4例)。分析其安全性和预后。在23例患者中，肿瘤初治时为III期，6例患者肿瘤初治时为IV期。22例接受放化疗，7例接受化疗，从最初治疗到手术的时间从2-60个月不等。初次治疗后5年总生存率为61%;手术后这一比例为51%。术后5年无复发生存率为49%。在无复发生存率方面，初治临床III期、病理0-II期或初治反应良好的患者预后较好。由此得出结论，虽然心肺并发症可以伴随抢救性手术，但手术总体上是安全的。特别是在对初始治疗反应良好的病例中，存活结果较好。
【DOI】10.1016/j.athoracsur..06.087
资料编译：李林峰
图文编辑：杨涵乐
质量把控：卢天健
